Selection criteria for large core trials: rationale for the ANGEL-ASPECT study design

Zeguang Ren,Xiaochuan Huo,Gaoting Ma,Xu Tong,Jay Kumar,Elliot Pressman,Wenhuo Chen,Guangxiong Yuan,Alvin Yi-Chou Wang,Ming Wei,Jiangang Zhang,Guangxian Nan,Qiyi Zhu,Yajie Liu,Liyong Zhang,Weigen Song,Zhiming Zhou,Guoqing Wang,Tianxiao Li,Jun Luo,En Wang,Wentong Ling,Dongsheng Ju,Cunfeng Song,Shu-Dong Liu,Liqiang Gui,Tong Li,Yan Liu,Junfeng Zhao,Zaiyu Guo,Hongbo Zheng,Yaxuan Sun,Na Xu,Yong Jun Wang,Zhongrong Miao
DOI: https://doi.org/10.1136/neurintsurg-2021-017798
IF: 4.8
2021-07-29
Journal of NeuroInterventional Surgery
Abstract:Two recently published JNIS commentaries1 2 on eligibility criteria for the clinical trials on patients with large core, acute ischemic stroke (AIS) with large vessel occlusion have caused some debate. Five trials were included.1 Our ongoing trial, ANGEL-ASPECT (NCT 04551664), which represents the only large core trial currently ongoing in the Chinese population, was not included in the discussion. One issue of the debate is the addition of CT perfusion (CTP)/diffusion-weighted image of magnetic resonance imaging (DWI-MRI) to the inclusion criteria, which only the SELECT-2 trial chose to adopt. This raised concern about whether patients already known to benefit from endovascular thrombectomy (EVT) are being randomized to EVT treatment or no treatment. Like the SELECT-2 trial, our ANGEL-ASPECT trial also added CTP/DWI-MRI to our inclusion criteria, but in a manner different from SELECT-2. Here we review the merits of ANGEL-ASPECT's design and suggest...
surgery,neuroimaging
What problem does this paper attempt to address?